SAN ANTONIO, Texas, Oct. 5 /PRNewswire/ -- C3i, the leader in technology services for the life sciences industry, and Bristol-Myers Squibb (BMS), a leading global biopharmaceutical company, will deliver a joint presentation discussing the advantages realized from upgrading to the newest version of Oracle Clinical/Remote Data Capture (OCRDC) software. The presentation will take place in October during the Oracle Health Sciences User Group conference (OHSUG) in San Antonio, TX October 10-13.
The presentation, titled "The Direct and Indirect Effects Upgrading to Zero Footprint has on Clinical Services", investigates several support areas of interest including site assessment, connectivity, laptop provisioning and software issues. Based on quantitative data gathered from BMS operations, Darlene Kalinowski, Associate Director, EDC Operations at BMS and Warren Ryanes, Account Director at C3i will demonstrate the benefits to clinical trial sponsors of upgrading to OCRDC 4.5.3. The "before" and "after" case study will show improvements in material, time and costs. The two presenters will highlight how a "zero footprint" and a decrease in 3rd party plug-ins results in cost savings in areas as diverse as shipping and connectivity, and in fewer support cases related to data entry, navigation, and reports.
"The Oracle Health Sciences User Group conference is a great place to exchange knowledge on Oracle products and related services .We are excited to share the positive experience of BMS with our colleagues from the industry," said Darlene Kalinowski. Warren Ryanes added: "BMS is a great partner. C3i is delighted to have the opportunity work with Darlene and her team to achieve such excellent results."
About C3i: Headquartered in Morristown, New Jersey, C3i Inc. has global operations centers in the United States, India and Bulgaria. Their 1000 employees provide consulting, systems implementation, technology training, multi-lingual help desk, ha
Copyright©2010 PR Newswire.
All rights reserved